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et al., 2016; Özdemir et al., 2015b).
Looking forward, Fig. 1 displays a vision of stratiﬁed medicine for
sepsis whereby individuals at sepsis risk are characterized acrossmulti-
ple “omes” from genome to proteome to metabolome, thus facilitating
multi-omics biomarker development (Higdon et al., 2015). Although
achieving “high resolution therapeutics” for precisionmedicine at a sin-1. Innovating Sepsis R&D: The “Omics” Turn
The Third International Consensus Deﬁnitions Task Force has re-
cently deﬁned sepsis as a “life-threatening organ dysfunction due to a
dysregulated host response to infection” (Singer et al., 2016). This
broad framework is a clear advancement over multiple, inconsistent
and narrow deﬁnitions employed in the past that tended to focus on in-
fection or pro-inﬂammatory processes alone. Pro- and anti-
inﬂammatory signaling occur simultaneously in host response to infec-
tion. Hence, we need in the current era a holistic and systems approach
to decipher the large interindividual and between-population variabil-
ity in pathogenesis of sepsis (Bauer et al., 2016; Wong et al., 2014).
Biomarkers that rapidly establish diagnosis and prognosis early in
the course of sepsis are of particular interest for proactive interventions.
Yet, the existing biomarker or diagnostic candidates fall quite short of
the desired clinical sensitivity and speciﬁcity (Sims et al., 2016). There
is no “typical” sepsis patient, nor a “universal therapy”, given that sepsis
is a complex syndrome driven by host-environment interactions. More-
over, that many of the clinical trials aimed at novel sepsis diagnostics
and therapeutics have failed is attributable, in part, to such hitherto un-
accounted host, infectious agent and environmental heterogeneity
enacting on each patient. Hadwe conducted clinical trials thatwere bet-
ter characterized for patient-to-patient variations in molecular etiolo-
gies and host responses, we would have been perhaps better poised toom.2016.03.006.
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. This is an open access article underdiagnose and prognosticate sepsis and its divergent outcomes (Sims
gle patient level might remain a long term objective, stratiﬁedmedicine
in cohorts of patients who share certain multi-omics biosignatures
would improve the timeliness for establishing diagnosis and prognosti-
cation in sepsis. Theranostics, i.e., diagnostics that help forecast treat-
ment outcomes, would be yet another deliverable and promise offered
by multi-omics biomarkers and stratiﬁed medicine (Higdon et al.,
2015; Özdemir and Kolker, 2016).2. Transcriptomics and Metagenomics: New Frontiers
Using a sophisticated multiplexed transcriptomics and three-step
biomarker development strategy in a German cohort, Bauer and col-
leagues report, in the present issue of EBioMedicine, on parallel occur-
rence of both pro- and anti-inﬂammatory changes in sepsis; they
suggest a composite biomarker set that might be used in clinical utility
studies in the future.(Bauer et al., 2016) This innovative study has con-
ﬁrmed their ﬁndings in an independent Greek cohort, a unique strength
thatmakes the studymore robust and generalizable as the Greek cohort
is geographically and genetically different than the German cohort. The
observations made by Bauer and colleagues lend support for the power
of omics systems science research in sepsis. It is also a distinct founda-
tional progress that can catalyze futuremulti-omics R&D integrating ge-
nomics, transcriptomics, proteomics and metabolomics research for
sepsis diagnostics and theranostics.
We shall take this opportunity to underscore that host transcriptomic
responses to sepsis, if coupled with tandem metagenomics characteri-
zation of the infectious pathogens, offer an unprecedented opportunity
for innovation. Metagenomics concerns high-throughput, culture-
independent, unbiased shotgun sequencing of DNA from environ-
mental samples. Put in other words, metagenomics can help identify
pathogens that escape the traditional culture-based methods in sepsis
diagnosis and prognostication.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. A strategic vision for rational diagnosis and prognostication of sepsis based on the
varying degrees of stratiﬁed medicine.
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We think that the study by Bauer et al. (2016) signals the anticipated
omics turn in the ﬁeld of sepsis. Yet, we shall not forget to characterize
the complex environmental factors that shape the multiple omes, in-
cluding the transcriptome. In this context, we have recently deﬁned
the concept of environtome as “the entire complement of elements ex-
ternal to the human host, from microbiome, ambient temperature and
weather conditions to government innovation policies, stock market
dynamics, human values, political power and social norms that collec-
tively shape the human host spatially and temporally” (Özdemir et al.,
2015b). Sepsis R&D would thus be well served, no doubt, by a dual at-
tention on multi-omics biomarkers as well as the sepsis environtome.
A related and rapidly emerging frontier is thenew ﬁeld of innovation
management. Innovations, by deﬁnition, are new, different, or unprece-
dented, and they often result in a “rupture”with the past products, pro-
cesses, and/or traditions. Indeed, it is an illuminating sign that we are
dealing with a genuine innovation, if and when our past experience ap-
pears no longer adequate in our ability to respond and steer an alleged
innovation.
Not surprisingly, innovation management and technology foresight
research have become important topics and specialized professions
over the past decade, as we currently witness a transition frommaterial
industries (e.g., textile, cement) to knowledge-based innovation
(e.g., information technology, e-learning), requiring new skills for
knowledge management worldwide (Birko et al., 2015).
Absent technology foresight and innovation management, new dis-
coveries do not always come to fruition in the form of product or pro-
cess innovations. Put in other words, there are many convincing
examples and data that have taught us valuable lessons that innovationsand new technologies cannot be left alone. Consider, for example, the
health research and biotechnology innovation sector. Out of nearly US
$ 240 billion spent annually on biomedical research globally, up to
85% is estimated as inefﬁcient (Chalmers and Glasziou, 2009). One of
the key reasons for such considerable research waste is poor steering
or management of health research and innovation so it does not invari-
ably lead to products or processes that have high relevance for the com-
munities (e.g., patients, doctors, nurses, citizens) who meant to beneﬁt
from it.
As we gaze into the future, we shall also note, brieﬂy, on innovation
in research funding for sepsis R&D. Innovative funding designs on unre-
solved and yet shared health problems such as sepsis impacting the so-
cieties worldwide can lend themselves well to crowdfunding (Özdemir
et al., 2015a). When coupled with sophisticated biological omics re-
search as reported by Bauer et al. (2016) crowdfunding could open up
new vistas for veritable funding of multi-omics research for discovery
and replication in independent population samples worldwide.
Sepsis is a serious concern and yet the emerging exciting frontiers in
biomedicine such as the study by Bauer et al. (2016) multi-omics
(Özdemir et al., 2015b; Higdon et al., 2015; Özdemir and Kolker,
2016) and metagenomics technologies (Birko et al., 2015) and innova-
tion foresight (Özdemir et al., 2015b; Özdemir and Kolker, 2016; Birko
et al., 2015) offer us hope for veritable progress.Conﬂict of Interest Statement
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